Cellectis (NASDAQ:CLLS) Announces Quarterly Earnings Results

Cellectis (NASDAQ:CLLS) released its earnings results on Monday. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03), Zacks reports. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. The firm had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. During the same period in the prior year, the business earned ($0.31) EPS.

Cellectis Stock Performance

NASDAQ:CLLS traded down $0.03 during midday trading on Wednesday, reaching $1.75. 123,752 shares of the company traded hands, compared to its average volume of 48,823. The firm has a market capitalization of $97.27 million, a price-to-earnings ratio of -1.38 and a beta of 3.10. The company has a fifty day moving average price of $2.08 and a 200 day moving average price of $2.28. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. Cellectis has a twelve month low of $1.75 and a twelve month high of $3.77.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. StockNews.com began coverage on Cellectis in a research note on Tuesday. They set a “sell” rating on the stock. Barclays reduced their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.